Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting

NEW YORK–(BUSINESS WIRE)– class= »bwalignl »>
Regulatory News:

Cellectis
(Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a
biopharmaceutical company focused on developing immunotherapies based on
gene edited CAR T-cells, today announced that data on its gene-edited
allogeneic off-the-shelf CAR T-cell immunotherapies (UCART) will be
presented at the ASGCT 20th Annual Meeting. The meeting will be held
from May 10th to 13th, 2017 in Washington, D.C., USA.

Oral presentation:

Development of Gene Edited Allogeneic CAR T-Cell Therapy
Philippe
Duchateau, PhD. Chief Executive Officer, Cellectis

Session: 300 – Clinical Advancement of Gene Editing-Moving New Science
to the Clinic – Organized by the Clinical Trials and Regulatory Affairs
Committee

Friday, May 12, 2017 from 8:35 AM to 9:10 AM EST
Lincoln 2, 3, 4

Poster presentations:

176
– Genome-Wide Analysis of TALEN® Activity in Primary Cells
Brian
Busser, Sonal Temburni, Aymeric Duclert, Philippe Duchateau and Laurent
Poirot

Session: Gene Targeting and Gene Correction I
Wednesday May 10,
2017 at 5:30 PM EST
Exhibit Hall A & B South

114 – UCART22: An Allogeneic Adoptive Immunotherapy for Leukemia
Targeting CD22 with CAR T-cells
Anne-Sophie Gautron,
Cécile Schiffer-Mannioui, Alan Marechal, Severine Thomas, Agnes Gouble,
Laurent Poirot, Julianne Smith

Session: Cancer-Immunotherapy, Cancer Vaccines I
Wednesday May 10,
2017 from 5:30 PM to 7:30pm EST
Exhibit Hall A & B South

372
– Manufacturing of Gene-Modified Mouse CAR T-Cells
Laurent
Poirot, Brian Busser, Sonal Temburni, Philippe Duchateau

Session: Gene Targeting and Gene Correction II
Thursday May 11,
2017 from 5:15 PM to 7:15 PM EST
Exhibit Hall A & B South

About Cellectis

Cellectis is a biopharmaceutical company focused on developing
immunotherapies based on gene-edited CAR T-cells (UCART). The company’s
mission is to develop a new generation of cancer therapies based on
engineered T-cells. Cellectis capitalizes on its 17 years of expertise
in genome engineering – based on its flagship TALEN® products and
meganucleases as well as its pioneering electroporation PulseAgile
technology – to create a new generation of immunotherapies. CAR
technologies are designed to target surface antigens expressed on cells.
Using its life-science-focused, pioneering genome-engineering
technologies, Cellectis’ goal is to create innovative products in
multiple fields and with various target markets.

Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE
Alternext market (ticker: ALCLS). To find out more about us, visit our
website: www.cellectis.com

Talking about gene editing? We do it. TALEN® is a registered trademark
owned by the Cellectis Group

Disclaimer

This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an offer
to buy or subscribe, for shares in Cellectis in any country. This press
release contains forward-looking statements that relate to the Company’s
objectives based on the current expectations and assumptions of the
Company’s management only and involve risk and uncertainties that could
cause the Company to fail to achieve the objectives expressed by the
forward-looking statements above.

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170425006830/en/